Comparing of ContraVir Pharmaceuticals Inc. (CTRV) and Celgene Corporation (NASDAQ:CELG)

ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) and Celgene Corporation (NASDAQ:CELG) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraVir Pharmaceuticals Inc. N/A 0.00 19.36M -1.42 0.00
Celgene Corporation 15.28B 4.12 4.05B 5.57 12.34

We can see in table 1 the earnings per share, gross revenue and valuation of ContraVir Pharmaceuticals Inc. and Celgene Corporation.

Profitability

Table 2 has ContraVir Pharmaceuticals Inc. and Celgene Corporation’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
ContraVir Pharmaceuticals Inc. 0.00% 0% -162%
Celgene Corporation 26.51% 56.8% 8.7%

Risk and Volatility

A 0.98 beta indicates that ContraVir Pharmaceuticals Inc. is 2.00% less volatile compared to Standard and Poor’s 500. In other hand, Celgene Corporation has beta of 1.47 which is 47.00% more volatile than Standard and Poor’s 500.

Liquidity

ContraVir Pharmaceuticals Inc. has a Current Ratio of 1.6 and a Quick Ratio of 1.6. Competitively, Celgene Corporation’s Current Ratio is 2.1 and has 2 Quick Ratio. Celgene Corporation’s better ability to pay short and long-term obligations than ContraVir Pharmaceuticals Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for ContraVir Pharmaceuticals Inc. and Celgene Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ContraVir Pharmaceuticals Inc. 0 0 0 0.00
Celgene Corporation 0 6 2 2.25

Competitively Celgene Corporation has an average target price of $88.17, with potential downside of -1.89%.

Institutional & Insider Ownership

The shares of both ContraVir Pharmaceuticals Inc. and Celgene Corporation are owned by institutional investors at 4.3% and 76.3% respectively. Insiders held 4.65% of ContraVir Pharmaceuticals Inc. shares. Competitively, insiders own roughly 0.33% of Celgene Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ContraVir Pharmaceuticals Inc. -13.11% -19.39% -42.37% -69.69% -86.85% -84.37%
Celgene Corporation -4.9% -8.98% -22.96% -12.32% -33.15% -34.19%

For the past year ContraVir Pharmaceuticals Inc. was more bearish than Celgene Corporation.

Summary

On 11 of the 11 factors Celgene Corporation beats ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.